Survivin expression and targeting in breast cancer

Surgical Oncology

Volumn 21, Issue 2, 2012, Pages 125-131

  Jha, Kumkum ^a   Shukla, Mridula ^a   Pandey, Manoj ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Apoptosis; EGFR; HER2; Inhibitors; Survivin

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CASPASE; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GATAPARSEN; GLYCOPROTEIN P; MESSENGER RNA; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 9; PRODIGNOSIN; PROTEIN KINASE B; PROTEIN VARIANT; RIBOZYME; SMALL INTERFERING RNA; SPC 3042; SURVIVIN; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; BODY FLUID; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; TREATMENT RESPONSE;

BREAST NEOPLASMS; CANCER VACCINES; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, CATALYTIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84860337543     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2011.01.001     Document Type: Review

References (79)

1. G. Ambrosini, C. Adida, and D.C. Altieri A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3 1997 917 921
2. B.M. Ryan, G.E. Konecny, S. Kahlert, H.J. Wang, M. Untch, and G. Meng Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 Ann Oncol 17 2006 597 604
3. F. Li, G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, and P.C. Marchisio Control of apoptosis and mitotic spindle checkpoint by Survivin Nature 396 1998 580 584
4. M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis 28 2007 1133 1139
5. N. Barnes, P. Haywood, P. Flint, W.F. Knox, and N.J. Bundred Survivin expression in insitu and invasive breast cancer relates to COX-2 expression and DCIS recurrence Br J Cancer 94 2006 253 258
6. S.Q. Zhang, S.Y. Qiang, W.B. Yang, J.T. Jiang, and Z.Z. Ji Expression of survivin in different stages of carcinogenesis and progression of breast cancer Ai Zheng 23 2004 697 700
7. L. Meijer, A. Jézéquel, and M. Roberge Survivin in apoptosis control and cell cycle regulation in cancer Prog Cell Cycle Resesarch 5 2003 447 452
8. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa1 Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 6 2000 127 134
9. L. O'Driscoll, R. Linehan, S.M. Kennedy, D. Cronin, R. Purcell, and S. Glynn Lack of prognostic significance of survivin, survivin- Delta Ex3, survivin-2B, galectin-3, bag-1, bax-alpha, and MRP-1 mRNAs in breast cancer Cancer Lett 201 2003 225 236
10. P.N. Span, F.C. Sweep, E.T. Wiegerinck, V.C. Tjan-Heijnen, P. Manders, and L.V. Beex Survivin is an independent prognostic marker for risk stratification of breast cancer patients Clin Chem 50 2004 1986 1993
11. S.M. Kennedy, L. O'Driscoll, R. Purcell, N. Fitz-simons, E.W. McDermott, and A.D. Hill Prognostic importance of survivin in breast cancer Br J Canc 88 2003 1077 1083
12. P.N. Span, V.C. Tjan-Heijnen, P. Manders, D. Van Tienoven, J. Lehr, and F.C. Sweep High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer Breast Cancer Res Treat 98 2006 223 230
13. J.A. Koziol, J.Y. Zhang, C.A. Casiano, X.X. Peng, F.D. Shi, and A.C. Feng Recursive partitioning as an approach to selection of immune markers for tumor diagnosis Clin Cancer Res 9 2003 120 126
14. J.Y. Zhang, C.A. Casiano, X.X. Peng, J.A. Koziol, E.K.L. Chan, and E.M. Tan Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens Cancer Epidemiol Biomark Prev 12 2003 136 143
15. M. Pennati, G. Colella, M. Folini, L. Citti, M.G. Daidone, and N. Zaffaroni Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis J Clin Investig 109 2002 285 286
16. M. Mesri, N.R. Wall, J. Li, R.W. Kim, and D.C. Altieri Cancer gene therapy using a survivin mutant adenovirus J Clin Investig 108 2001 981 990
17. A.Badran, A. Yoshida, K. Ishikawa, T. Goi, A. Yamaguchi, and T. Ueda Identification of a novel splice variant of the human anti-apoptosis gene survivin Biochem Biophys Res Commun 314 2004 902 907
18. C. Mahotka, M. Wenzel, E. Springer, H.E. Gabbert, and C.D. Gerharz Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties Cancer Res 59 1999 6097 6102
19. H. Caldas, L.E. Honsey, and R.A. Altura Survivin 2α: a novel Survivin splice variant expressed in human malignancies Mol Canc 4 2005
20. F. Vegran, R. Boidot, C. Oudin, J.M. Riedinger, and S. Lizard-Nacol Distinct expression of Survivin splice variants in breast carcinomas Int J Oncol 27 2005 1151 1157
21. P.N. Span, V.C. Tjan-Heijnen, J.J. Heuvel, J.B. de Kok, J.A. Foekens, and F.C. Sweep Do the survivin (BIRC5) splice variants modulate or Add to the prognostic value of total survivin in breast cancer? Clin Chem 16 2006 1693 1700
22. R. Boidot, F. Vegran, and S. Lizard-Nacol Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy Int J Mol Med 23 2009 285 291
23. S.M. Yie, B. Luo, N.Y. Ye, K. Xie, and S.R. Ye Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA Clin Exp Metastasis 23 2006 279 289
24. N. Guney, H.O. Soydine, D. Derin, F. Tas, H. Camlica, and D. Duranyildiz Serum and urine survivin levels in breast cancer Med Oncol 23 2006 335 339
25. K. Asanuma, R. Moriai, T. Yajima, A. Yagihashi, M. Yamada, and D. Kobayashi Survivin as a radioresistance factor in pancreatic cancer Jpn J Cancer Res 91 2000 1204 1209
26. M. Bache, D. Holzapfel, M. Kappler, H.J. Holzhausen, H. Taubert, and J. Dunst Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy Gynecol Oncol 104 2007 139 144
27. G. Capalbo, C. Rödel, R.H. Stauber, S.K. Knauer, M. Bache, and M. Kappler The role of survivin for radiation therapy prognostic and predictive factor and therapeutic target Strahlenther Onkol 183 2007 593 599
28. I.B. Roninson The role of the MDR1 (P-Glycoprotein) gene in multidrug resistance in vitro and in vivo Biochem Pharmacol 43 1992 95 102
29. M. Zhang, D.E. Latham, M.A. Delaney, and A. Chakravarti Survivin mediates resistance to antiandrogen therapy in prostate cancer Oncogene 24 2005 2474 2482
30. J. Tran, Z. Master, J.L. Yu, J. Rak, D. Dumont, and R.S. Kerbel A role for survivin in chemoresistance of endothelial cells mediated by VEGF Proc Natl Acad Sci U.S.A 99 2002 4349 4354
31. Z.H. Wang, Y.H. Xie, and H.B. Wang Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells Cancer Biol Ther 4 2005 716 719
32. M. Ikeguchi, T. Ueda, T. Sakatani, Y. Hirooka, and N. Kaibara Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma Diagn Mol Pathol 11 2002 33 40
33. F. Liu, S. Liu, S. He, Z. Xie, X. Zu, and Y. Jiang Survivin transcription is associated with P-glycoprotein/MDR1 over expression in the multidrug resistance of MCF-7 breastcancercells Oncol Rep 23 2010 1469 1475
34. F. Liu, Z.H. Xie, G.P. Cai, and Y.Y. Jiang The effect of survivin on multidrug resistance mediated by P-Glycoprotein in MCF-7 and its Adriamycin resistant cells Biol Pharm Bull 30 2007 2279 2283
35. E.A. Rakha, J.S. Reis-Filho, and I.O. Ellis Basal-like breast cancer: a critical review J Clin Oncol 26 2008 2568 2581
36. N. Hayashi, K. Asano, H. Suzuki, T. Yamamoto, N. Tanigawa, and S. Egawa Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo Prostate 65 2005 10 19
37. W. Zhang, X. Chen, and F. Qiu An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy J Huazhong Univ Sci Technolog Med Sci 23 2003 387 391
38. X. Huihua, Y.U. Shiying, Z. Liang, and X. Hua Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells Med Sci 27 2007 65 67
39. T.F. Ho, Y.T. Peng, S.M. Chuang, S.C. Lin, B.L. Feng, and C.H. Lu Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines Toxicol Appl Pharmacol 235 2009 253 260
40. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees Molecular portraits of human breast tumors Nature 406 2000 747 752
41. S. Gruvberger, M. Ringner, Y. Chen, S. Panavally, L.H. Saal, and A. Borg Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res 61 2001 5979 5984
42. M. Singh, M.J. Bleile, A.L. Shroyer, D. Heinz, E.A. Jarboe, and K.R. Shroyer Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast Appl Immunohistochem Mol Morphol 12 2004 296 304
43. G.G. Dogu, M. Ozkan, F. Ozturk, M. Dikilitas, O. Er, and A. Ozturk Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin Med Oncol 27 2010 34 39
44. K.J. Ranade, A.V. Nerurkar, M.D. Phulpagar, and N.V. Shirsat Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients Indian J Med Sci 63 2009 481 490
45. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
46. W. Dean-Colomb, and F.J. Esteva Her2-positive breast cancer: herceptin and beyond Eur J Cancer 44 2008 2806 2812
47. D.K. Morrison Integrating signals from RTKs to ERK//MAPK Oncogene 26 2007 3113 3121
48. D.A. Altomare, and J.R. Testa Perturbations of the AKT signaling pathway in human cancer Oncogene 24 2005 7455 7464
49. A. Siddiqa, L.M. Long, L. Li, R.A. Marciniak, and I. Kazhdan Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways BMC Cancer 8 2008 129
50. H. Zhu, G. Zhang, Y. Wang, N. Xu, S. He, and W. Zhang Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4- survivin pathway in ErbB2-overexpressed breast cancer cells Cancer Sci 2010 Feb 11 [Epub ahead of print]
51. V. Papanikolaou, D. Iliopoulos, I. Dimou, S. Dubos, K. Kappas, and S. Kitsiou-Tzeli Survivin regulation by HER2 through NF-kappaB and c-myc in irradiated breast cancer cells J Cell Mol Med 2010 Aug 16 [Epub ahead of print]
52. F. Kayasekcuk, T.X. Nursal, A. Polat, T. Noyan, S. Yildirim, and A. Tarim Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a) J Exp Clin Cancer Res 23 2004 105 112
53. L. Kleinberg, V.A. Florenes, J.M. Nesland, and B. Davidson Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions Am J Clin Pathol 128 2007 389 397
54. A. Nassar, D. Lawson, G. Cotsonis, and C. Cohen Survivin and Caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome Appl Immunohistochem Mol Morphol 16 2008 113 120
55. D.M. Sohn, S.Y. Kim, M.J. Baek, C.W. Lim, M.H. Lee, and M.S. Cho Expression of survivin and clinical correlation in patients with breast cancer Biomed Pharmacother 60 2006 289 292
56. F.S. Al-Joudi, Z.A. Iskandar, J. Hasnan, J. Rusli, Y. Kamal, and A.K. Imran Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast Singapore Med J 48 2007 607
57. A. Izawa, D. Kobayashi, S. Nasu, K. Saito, R. Moriai, and K. Asanuma Relevance of cerbB2, PLU-1, and survivin mRNA expression to diagnostic assessment of breast cancer Anticancer Res 22 2002 2965 2969
58. A.R. Hinnis, J.C. Luckett, and R.A. Walker Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients Br J Cancer 96 2007 639 645
59. T. Xiao-feng, L. Ji-hong, W. Li-fen, F. Xiao-Mei, and Y. Ji-hong Expression of survivin and E-Cadherin in breast cancer Chin J Canc Res 17 2005 103 106
60. T. Younis, K.D. Hache, D. Rayson, R. Dewar, S. Gray, and P.J. Barnes Survivin and COX-2 expression in male breast carcinoma Breast 18 2009 228 232
61. R. Wang, X. Wang, B. Li, F. Lin, K. Dong, and P. Gao Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo Breast Cancer Res Treat 117 2009 45 54
62. B. Ryan, N. O'Donovan, B. Browne, C. O'Shea1, J. Crown, and A.D.K. Hill Expression of survivin and its splice variants survivin-2B and survivin-DEx3 in breast cancer Br J Canc 92 2005 120 124
63. L. Kostadima, G. Pentheroudakis, G. Fountzilas, M. Dimopoulos, D. Pectasides, and H. Gogas Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival Breast Cancer Res Treat 100 2006 161 167
64. S. Nasu, A. Yagihashi, A. Izawa, K. Saito, K. Asanuma, and M. Nakamura Survivin mRNA expression in patients with breast cancer Anticancer Res 22 2002 1839 1843
65. A. Yagihashi, T. Ohmura, K. Asanuma, D. Kobayashi, N. Tsuji, and T. Torigoe Detection of autoantibodies to survivin and livin in sera from patients with breast cancer Clinica Chim Acta 362 2005 125 130
66. N. Tsuji, K. Fuuse, K. Asanuma, M. Furuya, K. Kondoh, and C. Kamagata Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer Breast Cancer Res Treat 87 2004 23 31
67. W.H. Hoffman, S. Biade, J.T. Zilfou, J. Chen, and M. Murphy Transcriptional repression of the anti-apoptotic survivin gene by wild type p53 J Biol Chem 2002
68. F. Végran, R. Boidot, C. Oudin, C. Defrain, M. Rebucci, and S. Lizard-Nacol Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancerp53 alterations and antiapoptotic survivin variants Oncogene 26 2007 290 297
69. A. Mirza, M. McGuirk, T.N. Hockenberry, Q. Wu, H. Ashar, and S. Black Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway Oncogene 21 2002 2613 2622
70. J.S. Chu, J.Y. Shew, and C.S. Huang Immunohistochemical analysis of survivin expression in primary breast cancers J Formos Med Assoc 103 2004 925 931
71. M. Promkan, G. Liu, P. Patmasiriwat, and S. Chakrabarty BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells Int J Cancer 125 2009 2820 2828
72. H. Doolittle, A. More, and D. Talbot Survivin directed anticancer Therapies - a review of pre-clinical data and early-phase clinical trials Eur Oncol 6 2010 10 14
73. H. Yao, Z.H. Huang, Z. Li, G.Q. Su, R. He, and F. Gao Specific killing effects of combination of double suicide gene and survivin antisense oligonucleotide on breast tumor cells and vein endothelial cells Zhonghua Wai Ke Za Zhi 45 2007 476 479
74. K.S. Choi, T.H. Lee, and M.H. Jung Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells Canc Gene Ther 10 2003 87 95
75. Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, and T. Sato An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, surviving Clin Cancer Res 8 2002 1731 1739
76. S. Idenoue, Y. Hirohashi, T. Torigoe, Y. Sato, Y. Tamura, and H. Hariu A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins Clin Canc Res 11 2005 1474
77. M. Grube, S. Moritz, E.C. Obermann, K. Rezvani, A. Mackensen, and R. Andreesen E, CD8+ Tcells reactive to survivin antigen in patients with Multiple Myeloma Clin Cancer Res 13 2007 1053 1060
78. R. Boidot, F. Végran, D. Jacob, S. Chevrier, M. Cadouot, and O. Feron The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism Oncogene 2010 [Epub ahead of print]
79. C. Chen, C. Liu, J. Zhang, Q. Yang, and F. Teng Grape seed extract inhibit proliferation of breast cancer cell MCF-7 and decrease the gene expression of survivin Zhongguo Zhong Yao Za Zhi 34 2009 433 437